November 20th 2020
The FDA naming convention and its utility are not well understood, and “poor” biosimilar knowledge may be partly to blame, investigators report.
November 16th 2020
Investigators said their study is valuable because biosimilar switching is likely to increase for economic reasons.
Investigators looked at adherence in patients who switched from reference infliximab during treatment for rheumatologic and gastrointestinal treatment.
November 9th 2020
A multibiomarker disease activity score looks at serum protein activity for a more sensitive evaluation of biosimilarity, investigators said at the American College of Rheumatology Convergence 2020 meeting.
November 7th 2020
Poster presentations at the American College of Rheumatology (ACR) Convergence 2020 meeting shed light on performance of adalimumab versions.
November 6th 2020
Separate studies including one on application methods for CT-P17 were reported at the American College of Rheumatology Convergence 2020 meeting.
